AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 32 min read$MAZENeutralLow

Coloma Jason V sold $160K of MAZE (indirect holdings)

Coloma Jason V (Chief Executive Officer) sold 6,090 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at $26.20 ($0.16M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Coloma Jason VJune 3, 2026
AI analysis
Relevance
6/10
Novelty
3/10
Actionability
Low
Sentiment · $MAZE
Neutral
Timing
Filed June 3, covering a June 1 sale at $26.1965/share.
Market alignment
Neutral-to-slightly negative (insider selling), but tempered by 10b5-1 pre-arrangement.
Why this matters for $MAZE

This is an insider sell under a 10b5-1 plan; it may slightly affect sentiment but is not a new fundamental catalyst.

Relevance context

Maze Therapeutics CEO sold 6,090 shares in an open-market transaction for about $159.5K, disclosed via Form 4.

Price-impact prediction

Low near-term impact; any reaction is likely muted given the pre-arranged 10b5-1 structure.

Background

SEC Form 4 discloses insider transactions; this one is an open-market sale by the CEO with a pre-arranged Rule 10b5-1 plan.

Why it matters

Traders may monitor for patterns in insider activity, but a single 10b5-1 sale typically carries limited incremental information.

Market relevance

Insider selling disclosed at $26.1965/share; likely sentiment noise rather than a fundamental driver.

Market effects

Sector

No clear sector read-through; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Alternative perspectives

Contrarian view

A 10b5-1 sale can reflect routine liquidity needs rather than bearish expectations, so price impact may be overstated.

Overlooked factors

The filing does not indicate whether other insiders bought/sold around the same period or whether there were concurrent operational catalysts.

Key entities

  • issuer
    Maze Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Coloma Jason V

    CEO and director who sold 6,090 shares.

Read at source← All news

Related articles

JUN 10
$MAZELow

Maze Therapeutics, Inc. (MAZE): Submission of Matters to a Vote of Security Holders

Maze Therapeutics, Inc. (MAZE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001842295 0001842295 2026-06-08 2026-06-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2

SEC EDGAR 8-K2 min
APR 8
$MAZEMed

San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial

H.C. Wainwright reiterated its Buy rating and $110 price target for Maze Therapeutics (MAZE) after KOL calls validated the HORIZON Phase 2 dataset, confirming the drug's efficacy in different patient cohorts. The data provides a clear path to pivotal trials, suggesting separate non-diabetic and diabetic arms with distinct endpoints. Analysts also noted the potential long-term advantages of MZE829 over competitors and anticipate that upcoming data from Vertex Pharmaceuticals' AMPLIFIED trial could further validate the APOL1 inhibition mechanism.

Streetwise Reports4 min